A 44-year-old female, with a background of cerebral palsy, epilepsy and learning disabilities, presented with multiple seizures and a persistently reduced consciousness level secondary to valproate-induced hyperammonaemic encephalopathy (plasma levels >50 μg/dl). Withdrawal of valproate and subsequent infusion of L-carnitine led to full recovery. Nonhepatic hyperammonaemia has been shown to be effectively treated by intravenous L-carnitine therapy by a series of case reports. To date, no randomised controlled trials have demonstrated this. Hyperammonaemic encephalopathy is possibly a more common presentation than expected that is currently underdiagnosed and exacerbated by valproate.
MakelaAL, LangH, KorpelaP. Toxic encephalopathy with hyperammonaemia during high-dose salicylate therapy. Acta Neurol Scand1980; 61: 146–56.
5.
NottL, PriceTJ, PittmanK. Hyperammonemia encephalopathy: an important cause of neurological deterioration following chemotherapy. Leuk Lymphoma2007; 48: 1702–11.
UpadhyayR, BleckTP, BuslKM. Hyperammonemia: what urea-lly need to know: case report of severe noncirrhotic hyperammonemic encephalopathy and review of the literature. Case Rep Med2016; 2016:8512721.
8.
BohanTP, HeltonE, McDonaldI. Effect of L-carnitine treatment for valproate-induced hepatotoxicity. Neurology2001; 56: 1405–9.
9.
PerrottJ, MurphyNG, ZedPJ. L-carnitine for acute valproic acid overdose: a systematic review of published cases. Ann Pharmacother2010; 44: 1287–93.
CattaneoCI, RessicoF, ValsesiaR. Sudden valproate-induced hyperammonemia managed with L-carnitine in a medically healthy bipolar patient: essential review of the literature and case report. Medicine (Baltimore)2017; 96: e8117.
